By Micah Halpern
I've Been Thinking:
Enlivex is an Israeli biotech company specializing in immunotherapy. The company is working on a cure for COVID. They just completed Phase II of trials and the results are very promising.
The drug Enlivex is testing and improving is called Allocetra.
In this second stage, sixteen patients who were all in severe or critical condition survived a 28 day experimental Phase II treatment. At the end of the trial, two of the sixteen patients were in still in critical condition and on ventilators. The other fourteen patients were fully recovered, healthy and released from the hospital.
The average duration of hospitalization after receiving Allocetra, for those who were discharged, was 5.3 days.
In the Phase I trial of the drug, five patients were all in severe condition when they started receiving Allocetra. Their average stay in the hospital was 10 days and they all recovered.
The most significant finding in this study is the improvement that was seen from the first to the second trial. Nearly a 50% improvement. And the time spent in the hospital once the drug was administered went from ten days to five.
There is hope.
Read my latest book THUGS. It's easy. Just click.
http://www.amazon.com/s/ref=nb_ss_gw?url=search-alias%3Daps&field-keywords=halpern%2C+micah
To reprint my essays contact sales (at) www.featurewell.com
No comments:
Post a Comment